For decades, pharma companies have relied on sales visits as the primary channel to engage with doctors, believing that these interactions shape prescribing behaviors. However, the reality of modern medical decision-making has evolved, and the actual impact of sales visits remains unclear.
Notably, a recent report emphasizes that customer experience accounts for 35% of prescription decision-making. This underscores the importance for pharmaceutical companies to move beyond conventional sales visits and focus on delivering high-quality, evidence-based information that aligns with HCPs' needs.
Doctors operate in a complex environment where multiple factors influence their choices. Drug formularies, clinical pathways, R&D advancements, and updates from clinical trials play a crucial role in prescribing decisions. Yet, pharma companies often focus on traditional promotional tactics, assuming that doctors prioritize direct engagement over evidence-based practice.
In today's landscape, healthcare professionals are increasingly turning to digital resources, peer-reviewed studies, and real-world data rather than relying solely on sales representatives. Clinical trial results, safety profiles, and cost-effectiveness assessments are more influential than ever. Furthermore, regulatory pressures and hospital policies limit the direct impact of in-person visits, making it imperative for pharma companies to rethink their engagement strategies.
Pharma must shift toward more personalized, data-driven, and value-based communication to truly understand what doctors want. Providing relevant, timely, and scientifically robust information through digital channels, on-demand content, and AI-driven insights can foster a more meaningful connection with HCPs.
The industry must ask itself: Are we engaging doctors in the way they need, or in the way we assume they want? The future of pharma-doctor interactions depends on aligning with the evolving needs of healthcare professionals rather than clinging to outdated models of influence.